为优先考虑克服胰腺癌免疫疗法的耐药性候选化合物的计算框架
Fangyoumin Feng1, Tian He2, Ping Lin1
1Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.
Cell reports. Medicine
|August 6, 2025
概括
一个新的计算框架,IGeS-BS,识别化合物来克服免疫疗法耐药性. 两种化合物,SB-366791和CGP-60474,在临床前模型中通过激活免疫细胞对抗癌症,显示出有希望.
科学领域:
- 计算生物学是一种计算生物学.
- 癌症研究 癌症研究
- 免疫治疗是一种免疫疗法.
背景情况:
- 免疫疗法耐药性是癌症治疗的一个主要挑战.
- 已发现很少有协同作用的药物可以增强免疫治疗的疗效.
研究的目的:
- 开发一个计算框架 (IGeS-BS) 来识别克服免疫疗法耐药性的化合物.
- 为药物发现创造一个免疫增强的环境.
主要方法:
- 对1000个转录组进行元分析,以确定预测免疫疗法反应的瘤微环境 (TME) 签名.
- 使用TCGA和LINCS数据集生成免疫增强景观,用于>10,000种化合物和13种癌症类型.
- 在肝细胞癌和其他癌症中高得分化合物的体外和体内验证.
主要成果:
- 确定了33个TME签名,用于强大的免疫疗法反应预测.
- 发现了两种化合物,SB-366791和CGP-60474,可以显著减轻肝细胞癌对抗PD1治疗的耐药性.
- 证明这些化合物通过激活免疫细胞来增强免疫疗法.
结论:
- IGeS-BS框架有效地识别了增强免疫疗法反应的化合物.
- SB-366791和CGP-60474是克服免疫疗法耐药性的组合治疗的有希望的候选人.
- 这种方法为发现新型免疫增强剂提供了有价值的工具.
更多相关视频
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10.7K
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
5.1K
相关概念视频
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:27Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K